ForteBio is now part of the Sartorius group. Click here for more

Resources Search

Filter By:

Search Results

Results 31 - 40 of 840

A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang, et al., March 2020 Read More

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Xiaolong Tian, et al., 9(1): 382–385, Emerg Microbes Infect. 2020 The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including…

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp, et al., Vol. 367, Issue 6483, pp. 1260-1263 , Science  13 Mar 2020 Read More

Rapid, at-line AAV Virus Titer Assay

ForteBio has developed a quick, high-throughput, and robust AAV2 capsid quantification method, capable of virus titer determination in samples along the purification process.

Rapid, at-line AAV2 virus Quantitation Advances Bioprocessing in Gene Therapy

In this application note, we describe the development of an assay for quantifying AAV2 virus particles in gene therapy.

Advancing Upstream Bioprocessing with the Octet Platform

This document describes the optimization of upstream bioprocessing into higher production of target biologics with the Octet RED384 and HTX systems.

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.